Ann: H1 2023 Preclinical and Clinical Programs Update, page-55

if you change the solubility of the drug ("RC 110 tends to precipitate in peripheral veins"), you have potentially changed the performance, and therefore due diligence would warrant confirmation of no change to performance.
My point about CVC Vs PIVC is about infection, and the advantages in the latter, and in no way related to metabolism.
Being able to administer peripherally is easier and less risky. The fact that bisantrene can be administered via this route route means that is also less irritant from a phlebitis point of view which is a big problem for most chemotherapeutics and a point of difference.
As i said, this is a very attractive feature and i still remain confident of outsized returns